Edwards’ SAPIEN 3 Ultra RESILIA Valve demonstrates positive outcome

India embraces AI and Virtual Care to bridge workforce gaps in healthcare: Philips Future Health Index India 2024

Merck announces pivotal phase 3 ZENITH trial evaluating WINREVAIR

WINREVAIR met primary endpoint of time to first morbidity or mortality event for the treatment of patients with pulmonary arterial hypertension (PAH) functional class III or IV at high risk of mortality

AbbVie provides update on Phase 2 results for Emraclidine in schizophrenia

Emraclidine was well-tolerated with an adverse event profile consistent with Phase 1b trial

Roche’s Vabysmo improved vision in underrepresented populations with DME in a first-of-its-kind study

Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies

FDA approves VYALEV for adults living with advanced parkinson's disease

VYALEV is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson's disease

AIIMS, New organises conference on ‘Advancing Oral Health in India’

Poor oral health (periodontal disease) impacts nearly 51% of Indians

FDA approves Bristol Myers Squibb’s Cobenfy

A first-in-class muscarinic agonist for the treatment of schizophrenia in adults

Sun Pharma presents clinical efficacy and safety data in severe dermatological conditions at 2024 EADV Congress

The company will also share results in two additional posters for deuruxolitinib

India highlights need for global cooperation to address AMR threat at UNGA

AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine